Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
The purpose of this registry is to better understand how patients diagnosed with A-Fib are cared for by their health care provider, and what happens to them as a result of the care they receive.
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Principal Investigator: Marcus Williams
For more information, please call 201-447-8453.
A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors
The purpose of this study is to see if dronedarone 400mg twice a day can reduce cardiovascular events, such as stroke, myocardial infarction, a clotting of arteries called systemic arterial embolism, hospitalization for cardiovascular reason, or death from a cardiovascular cause in patients 65 years of age or older with permanent atrial fibrillation and additional cardiovascular diseases or risk factor.
Sponsor: Sanofi Aventis
Principal Investigator: Marcus Williams, MD
Co-Investigators: Arvind Agarwal,MD, Navin Budhwani, MD, Michael Kesselbrenner, MD, Dennis Reison, MD, Janet Strain, MD
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multinational Trial to Assess the Prevention of Thrombotic Events with Tricagrelor Compared to Placebo on a Backround of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction
The purpose of this study is to evaluate the use of a new drug called Tricagrelor in addition to aspirin in patients with a history of a heart attack between 1 and 3 years ago.
Sponsor: AstraZeneca LP
Principal Investigator: Janet Strain, MD
Co-Investigators: Arvind Agarwal, MD, Joseph Wiedermann, MD, Michael Kesselbrenner, MD, Elliott Lichtstein, MD, Navin Budhwani, MD, Dennis Reison, MD
A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen
The purpose of this study is to assess the effects of long-term use of celecoxib compared to ibuprofen and naproxen on cardiovascular, gastrointestinal, and renal safety. Additionally, the ability of each drug to control arthritis pain effectively will be evaluated.
Principal Investigator: Michael Kesselbrenner, MD
Sub-Investigators: Arvind Agarwal, MD; Navin Budhwani, MD; Edward Ewald, MD; Howard Goldschmidt, MD; Evan Leibowitz, MD; Robert Saporito, MD; Alan Simon, MD; Janet Strain, MD; Marcus Williams, MD